Evidence map›Paper›PMID 33397474›Full record

ArticleAlzheimer's research & therapy2021

Region-specific amyloid-β accumulation in the olfactory system influences olfactory sensory neuronal dysfunction in 5xFAD mice.

Gowoon Son, Seung-Jun Yoo, Shinwoo Kang, Ameer Rasheed, Da Hae Jung, Hyunjun Park, Bongki Cho, Harry W M Steinbusch, Keun-A Chang, Yoo-Hun Suh and 1 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Gowoon SonDepartment of Brain & Cognitive Sciences, Graduate School, Daegu Gyeungbuk Institute of Science and Technology (DGIST), Daegu, Republic of Korea.
Seung-Jun YooDepartment of Brain & Cognitive Sciences, Graduate School, Daegu Gyeungbuk Institute of Science and Technology (DGIST), Daegu, Republic of Korea.
Shinwoo KangDepartment of Pharmacology, College of Medicine, Gachon University, Incheon, Republic of Korea.
Ameer RasheedDepartment of Brain & Cognitive Sciences, Graduate School, Daegu Gyeungbuk Institute of Science and Technology (DGIST), Daegu, Republic of Korea.
Da Hae JungDepartment of Brain & Cognitive Sciences, Graduate School, Daegu Gyeungbuk Institute of Science and Technology (DGIST), Daegu, Republic of Korea.
Hyunjun ParkDepartment of Pharmacology, College of Medicine, Gachon University, Incheon, Republic of Korea.
Bongki ChoDepartment of Brain & Cognitive Sciences, Graduate School, Daegu Gyeungbuk Institute of Science and Technology (DGIST), Daegu, Republic of Korea.
Harry W M SteinbuschDepartment of Brain & Cognitive Sciences, Graduate School, Daegu Gyeungbuk Institute of Science and Technology (DGIST), Daegu, Republic of Korea.
Keun-A ChangDepartment of Pharmacology, College of Medicine, Gachon University, Incheon, Republic of Korea.
Yoo-Hun SuhDepartment of Pharmacology, College of Medicine, Gachon University, Incheon, Republic of Korea.
Cheil MoonDepartment of Brain & Cognitive Sciences, Graduate School, Daegu Gyeungbuk Institute of Science and Technology (DGIST), Daegu, Republic of Korea. cmoon@dgist.ac.kr.ORCID 0000-0002-9741-7229
Daegu Gyeongbuk Institute of Science and Technology · KRGachon University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyposmia in Alzheimer's disease (AD) is a typical early symptom according to numerous previous clinical studies. Although amyloid-β (Aβ), which is one of the toxic factors upregulated early in AD, has been identified in many studies, even in the peripheral areas of the olfactory system, the pathology involving olfactory sensory neurons (OSNs) remains poorly understood.

methodsHere, we focused on peripheral olfactory sensory neurons (OSNs) and delved deeper into the direct relationship between pathophysiological and behavioral results using odorants. We also confirmed histologically the pathological changes in 3-month-old 5xFAD mouse models, which recapitulates AD pathology. We introduced a numeric scale histologically to compare physiological phenomenon and local tissue lesions regardless of the anatomical plane.

resultsWe observed the odorant group that the 5xFAD mice showed reduced responses to odorants. These also did not physiologically activate OSNs that propagate their axons to the ventral olfactory bulb. Interestingly, the amount of accumulated amyloid-β (Aβ) was high in the OSNs located in the olfactory epithelial ectoturbinate and the ventral olfactory bulb glomeruli. We also observed irreversible damage to the ectoturbinate of the olfactory epithelium by measuring the impaired neuronal turnover ratio from the basal cells to the matured OSNs.

conclusionsOur results showed that partial and asymmetrical accumulation of Aβ coincided with physiologically and structurally damaged areas in the peripheral olfactory system, which evoked hyporeactivity to some odorants. Taken together, partial olfactory dysfunction closely associated with peripheral OSN's loss could be a leading cause of AD-related hyposmia, a characteristic of early AD.

Indexed as

Olfactory Receptor NeuronsAmyloid beta-PeptidesAnimalsAxonsMiceMice, TransgenicOlfactory BulbSmellAmyloid beta-Peptides5xFADAlzheimer’s diseaseCa2+ imagingNeuronal turnoverOdor detection testOlfactory dysfunctionOlfactory sensory neuronTopographic analysisZonal organizationβ-amyloid

Identifiers

PMID33397474
PMCPMC7784287
OpenAlexW3118924852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.